Stueland Katherine 4

What Happened
Katherine Stueland, CEO of GeneDx Holdings (WGS), had RSUs vest/convert to stock (reported as derivative exercises/conversions) and then sold shares to satisfy tax withholding. She acquired 30,671 shares through RSU settlement (11,921 on 2026-03-15 and 18,750 on 2026-03-16) at $0.00 per share (per footnote: RSUs settle for no consideration). On 2026-03-16 she sold a total of 17,179 shares in open-market trades for aggregate proceeds of approximately $1,319,291 (7,178 @ $76.35 → $548,035; 9,229 @ $77.05 → $711,090; 772 @ $77.94 → $60,166). The filing notes these sales were "sell to cover" tax withholding and not discretionary.

Key Details

• Transaction dates: RSU settlement/exercises on 2026-03-15 and 2026-03-16; open-market sales on 2026-03-16.
• Sale prices: weighted averages reported; individual ranges per footnotes — $75.735–$76.73, $76.74–$77.71, and $77.75–$78.16 (see footnotes F3–F5).
• Shares: acquired 30,671 via RSU settlement; sold 17,179 shares for ~ $1.32M.
• Holdings after transaction: 58,447 shares beneficially owned plus RSUs representing rights to up to 414,695 shares and options to purchase up to 107,610 shares (per F6).
• Notable footnotes: F1 (RSUs convert to 1 share each for no consideration), F2 (sales were sell-to-cover for tax withholding), F3–F5 (weighted-average price ranges), F7/F8 (vesting schedules).
• Filing timeliness: no late-filing flag indicated in the data provided.

Context
This was a routine RSU settlement followed by a sell-to-cover: RSUs converted to shares (recorded as derivative exercises/conversions at $0), and a portion of the newly issued shares were sold to satisfy tax withholding obligations. Such sell-to-cover transactions are common after vesting and do not necessarily signal the insider’s view on the company’s prospects.